FONR Quote, Financials, Valuation and Earnings

ProPhase Labs has a net margin of 9.23% compared to Fonar's net margin of -209.38%. Fonar's return on equity of 5.33% beat ProPhase Labs's return on equity of -144.22%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3609.68%. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

Fonar has a beta of 0.998, which suggesting that the stock is 0.238% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.412, suggesting its less volatile than the S&P 500 by 141.195%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $27.2M, which are larger than ProPhase Labs quarterly revenues of $1.4M. Fonar's net income of $2.5M is lower than ProPhase Labs's net income of $4M. Notably, Fonar's price-to-earnings ratio is 12.87x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.99x versus 2.02x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific has a net margin of 9.23% compared to Fonar's net margin of 14.54%. Fonar's return on equity of 5.33% beat Thermo Fisher Scientific's return on equity of 13.49%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Thermo Fisher Scientific has an analysts' consensus of $549.78 which suggests that it could grow by 32.06%. Given that Thermo Fisher Scientific has higher upside potential than Fonar, analysts believe Thermo Fisher Scientific is more attractive than Fonar.

Fonar has a beta of 0.998, which suggesting that the stock is 0.238% less volatile than S&P 500. In comparison Thermo Fisher Scientific has a beta of 0.769, suggesting its less volatile than the S&P 500 by 23.079%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific offers a yield of 0.39% to investors and pays a quarterly dividend of $0.43 per share. Fonar pays -- of its earnings as a dividend. Thermo Fisher Scientific pays out 9.2% of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fonar quarterly revenues are $27.2M, which are smaller than Thermo Fisher Scientific quarterly revenues of $10.4B. Fonar's net income of $2.5M is lower than Thermo Fisher Scientific's net income of $1.5B. Notably, Fonar's price-to-earnings ratio is 12.87x while Thermo Fisher Scientific's PE ratio is 24.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.99x versus 3.71x for Thermo Fisher Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of 9.23% compared to Fonar's net margin of 6.16%. Fonar's return on equity of 5.33% beat Veracyte's return on equity of 2.85%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte has an analysts' consensus of $40.33 which suggests that it could grow by 60.24%. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Fonar has a beta of 0.998, which suggesting that the stock is 0.238% less volatile than S&P 500. In comparison Veracyte has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.062%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $27.2M, which are smaller than Veracyte quarterly revenues of $114.5M. Fonar's net income of $2.5M is lower than Veracyte's net income of $7M. Notably, Fonar's price-to-earnings ratio is 12.87x while Veracyte's PE ratio is 61.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.99x versus 4.30x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 9.23% compared to Fonar's net margin of -67.19%. Fonar's return on equity of 5.33% beat XWELL's return on equity of -153.74%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 586.28%. Given that XWELL has higher upside potential than Fonar, analysts believe XWELL is more attractive than Fonar.

Fonar has a beta of 0.998, which suggesting that the stock is 0.238% less volatile than S&P 500. In comparison XWELL has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $27.2M, which are larger than XWELL quarterly revenues of $7M. Fonar's net income of $2.5M is higher than XWELL's net income of -$4.7M. Notably, Fonar's price-to-earnings ratio is 12.87x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.99x versus 0.15x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.